

<b>CMS Manual System</b>	<b>Department of Health &amp; Human Services (DHHS)</b>
<b>Pub 100-20 One-Time Notification</b>	<b>Centers for Medicare &amp; Medicaid Services (CMS)</b>
<b>Transmittal 13400</b>	<b>Date: September 5, 2025</b>
	<b>Change Request 14197</b>

**Transmittal 13375 issued August 21, 2025, is being rescinded and replaced by Transmittal 13400, dated September 5, 2025, to update the policy section and to update NCD 110.18 Aprepitant for Chemotherapy Induced Emesis business requirement 14197.3 to mark the DME MACs as responsible. All other information remains the same.**

**SUBJECT: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to National Coverage Determinations (NCDs)—January 2026 Update- CR 1 of 2**

**I. SUMMARY OF CHANGES:** The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 coding changes specific to NCDs.

**EFFECTIVE DATE: January 1, 2026**

*\*Unless otherwise specified, the effective date is the date of service.*

**IMPLEMENTATION DATE: January 5, 2026**

*Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.*

**II. CHANGES IN MANUAL INSTRUCTIONS:** (N/A if manual is not updated)

R=REVISED, N=NEW, D=DELETED-Only One Per Row.

<b>R/N/D</b>	<b>CHAPTER / SECTION / SUBSECTION / TITLE</b>
N/A	N/A

### **III. FUNDING:**

#### **For Medicare Administrative Contractors (MACs):**

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

### **IV. ATTACHMENTS:**

**One Time Notification**

# Attachment - One-Time Notification

Pub. 100-20	Transmittal: 13400	Date: September 5, 2025	Change Request: 14197
-------------	--------------------	-------------------------	-----------------------

**Transmittal 13375 issued August 21, 2025, is being rescinded and replaced by Transmittal 13400, dated September 5, 2025, to update the policy section and to update NCD 110.18 Aprepitant for Chemotherapy Induced Emesis business requirement 14197.3 to mark the DME MACs as responsible. All other information remains the same.**

**SUBJECT: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to National Coverage Determinations (NCDs)—January 2026 Update- CR 1 of 2**

**EFFECTIVE DATE: January 1, 2026**

*\*Unless otherwise specified, the effective date is the date of service.*

**IMPLEMENTATION DATE: January 5, 2026**

**I. SUMMARY OF CHANGES:** The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 coding changes specific to NCDs.

## **II. GENERAL INFORMATION**

**A. Background:** The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received. Previous NCD coding changes appear in ICD-10 quarterly updates that can be found at:  
<https://www.cms.gov/medicare/coverage/determination-process/basics/icd-10>

along with other CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, longstanding NCD process.

**B. Policy:** Edits to ICD-10, and other coding updates specific to NCDs, will be included in subsequent quarterly releases as needed. No policy-related changes are included with these updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. Please follow the link below for the NCD spreadsheets included with this CR: <https://www.cms.gov/files/zip/Medicare-Coverage-DeterminationProcess-CR14197.zip>

Clarification: Coding (as well as payment) is a separate and distinct area of the Medicare Program from coverage policy/criteria. Revisions to codes within an NCD are carefully and thoroughly reviewed and vetted by the Centers for Medicare & Medicaid Services and are not intended to change the original intent of the NCD. The exception to this is when coding revisions are released as official implementation of new or reconsidered NCD policy following a formal national coverage analysis.

Note: The translations from ICD-9 to ICD-10 are not consistent one-to-one matches, nor are all ICD-10 codes appearing in a complete General Equivalence Mappings (GEMs)\* mapping guide or other mapping guides appropriate when reviewed against individual NCD policies. \*GEMs mapping is no longer provided by CMS as of October 1, 2019. In addition, for those policies that expressly allow Medicare Administrative Contractor (MAC) discretion, there may be changes to those NCDs based on current review of those NCDs against ICD-10 coding. For these reasons, there may be certain ICD-9 codes that were once considered appropriate prior to ICD-10 implementation that are no longer considered acceptable.

Note/Clarification: A/B MACs Part A and A/B MACs Part B shall complete all tasks that involve updates to local system edits/tables associated with the attached NCDs in this CR.

Note/Clarification: A/B MACs shall use default Council for Affordable Quality Healthcare (CAQH) Committee on Operating Rules for Information Exchange (CORE) messages where appropriate: Remittance Advice Remark Codes (RARC) N386 with Claim Adjustment Reason Code (CARC) 50, 96, and/or 119. See latest CAQH CORE update. When denying claims associated with the attached NCDs, except where otherwise indicated, A/B MACs shall use: Group Code PR (Patient Responsibility) assigning financial responsibility to the beneficiary (if a claim is received with occurrence code 32, or with occurrence code 32 and a GA modifier, indicating a signed Advance Beneficiary Notice (ABN) is on file). Group Code CO (Contractual Obligation) assigning financial liability to the provider (if a claim is received with a GZ modifier indicating no signed ABN is on file). For modifier GZ, use CARC 50 and Medicare Summary Notice (MSN) 8.81 per instructions in CR 7228/TR 2148.

### III. BUSINESS REQUIREMENTS TABLE

*"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.*

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	
14197.1	NCD 20.16 Cardiac Output Monitoring by Thoracic Electrical Bioimpedance (TEB)  Contractors shall add ICD-10 CM codes I27.840, I27.841, I27.848, and I27.849 to the covered diagnosis code list effective October 1, 2025.  See attached spreadsheet.	X	X			X	X			
14197.2	NCD 90.2 Next Generation Sequencing (NGS)  Contractors shall add ICD-10 CM codes C50.A1 and C50.A2 for FoundationOne® CDx (CPT 0037U), MI Cancer Seek™ (CPT 0211U), FoundationOne® Liquid CDx (CPT 0239U), Guardant360® CDx (CPT 0242U), xT CDx Tempus AI	X	X							

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	
	(CPT 0473U), and TruSight Oncology Comprehensive (CPT 0543U) effective October 1, 2025.  See attached spreadsheet.									
14197.3	NCD 110.18 Aprepitant for Chemotherapy Induced Emesis  Contractors shall add ICD-10 diagnosis codes C50.A1 and C50.A2 effective October 1, 2025.  See attached spreadsheet.	X			X	X				
14197.4	NCD 190.3 Cytogenetic Studies  Contractors shall end-date ICD-10 CM code Q99.8 effective September 30, 2025.  Add ICD-10 CM codes Q99.811, Q99.812, Q99.813, Q99.818, Q99.89, QA0.0101, QA0.0102, QA0.0109, QA0.011, QA0.012, QA0.0131, QA0.0139, QA0.0141, QA0.0142, QA0.0149, QA0.0151, QA0.0159, QA0.8, Z15.05, Z15.060, Z15.068, Z15.07, and Z15.3 to Nationally Covered Indications effective October 1, 2025.  Add C50.A1 and C50.A2 to MAC Discretionary Covered	X	X			X	X			

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	
	<p>Indications effective October 1, 2025.</p> <p>See attached spreadsheet.</p>									
14197.5	<p>NCD 210.2 Screening Pap Smears and Pelvic Examinations for Early Detection of Cervical or Vaginal Cancer</p> <p>Contractors shall add ICD-10 diagnosis codes Z84.A and Z91.B to PAP High Risk and Pelvic Exam effective October 1, 2025.</p> <p>Contractors shall add ICD-10 diagnosis codes R87.810 and R87.612 to PAP High Risk and Pelvic Exam effective October 1, 2015.</p> <p>See attached spreadsheet.</p>	X	X						X	
14197.6	<p>NCD 210.3 Colorectal Cancer Screening Tests</p> <p>Contractors shall add ICD-10 CM codes Z15.060 and Z15.068 to list 1 effective October 1, 2025 and revise descriptor for ICD-10 CM code Z83.718 in list 1 effective October 1, 2025.</p>	X	X			X	X			

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	
	See attached spreadsheet.									
14197.7	<p>NCD 210.15</p> <p>Preexposure Prophylaxis (PrEP) Using Antiretroviral Therapy to Prevent Human Immunodeficiency Virus (HIV) Infection</p> <p>Contractors shall add coverage for Yeztugo (Lenacapavir) HCPCS code J0738 for the injectable (Injection, lenacapavir, 1 mg, FDAapproved prescription, only for use as HIV pre-exposure prophylaxis (not for use as treatment for HIV) effective October 1, 2025.</p> <p>And</p> <p>J0752 for the oral form (Oral, lenacapavir, 300 mg, FDA approved prescription, only for use as HIV pre-exposure prophylaxis (not for use as treatment for HIV) effective October 1, 2025.</p> <p>See attached spreadsheet.</p>	X	X			X	X			
14197.7.1	Contractors shall update their respective editing associated with NCD 210.15 to ensure new PrEP drug codes J0738 (injectable) and J0752 (oral) are billable and adjudicated under the same conditions as existing PrEP injectable and					X	X			

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	
	oral drug codes (i.e., allowed ICD-10 codes, supply code requirements, TOBs, etc.)									
14197.8	Contractors shall not search claims but may adjust claims that are brought to their attention.	X	X							

#### IV. PROVIDER EDUCATION

Medicare Learning Network® (MLN): CMS will develop and release national provider education content and market it through the MLN Connects® newsletter shortly after we issue the CR. MACs shall link to relevant information on your website and follow IOM Pub. No. 100-09 Chapter 6, Section 50.2.4.1 for distributing the newsletter to providers. When you follow this manual section, you don't need to separately track and report MLN content releases. You may supplement with your local educational content after we release the newsletter.

**Impacted Contractors:** A/B MAC Part A, A/B MAC Part B

#### V. SUPPORTING INFORMATION

**Section A: Recommendations and supporting information associated with listed requirements:** N/A

*"Should" denotes a recommendation.*

X-Ref Requirement Number	Recommendations or other supporting information:
--------------------------	--

**Section B: All other recommendations and supporting information:** N/A

#### VI. CONTACTS

**Post-Implementation Contact(s):** Contact your Contracting Officer's Representative (COR).

#### VII. FUNDING

##### Section A: For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

**ATTACHMENTS:** Refer to Section B.